Forma Therapeutics Reports Third Quarter 2020 Financial Results and Provides Business Update – Galveston County Daily News

WATERTOWN, Mass.--(BUSINESS WIRE)--Nov 12, 2020--

Forma Therapeutics Holdings, Inc. (Nasdaq: FMTX), a clinical-stage biopharmaceutical company focused on rare hematologic diseases and cancers, today reported financial results for the third quarter ended September 30, 2020. The company also highlighted recent progress and upcoming milestones for its pipeline programs.

We are very pleased with our strong pipeline progress during the quarter amid such challenging times, said Frank Lee, President and Chief Executive Officer of Forma. We look forward to presenting new data from our ongoing Phase 1 trial of FT-4202 in sickle cell disease at the ASH meeting in December, as well as beginning enrollment of patients for our Phase 1 trial of FT-7051 in men living with metastatic castration-resistant prostate cancer. The recent positive top-line results from the olutasidenib registrational Phase 2 clinical trial in relapsed/refractory acute myeloid leukemia with an IDH1 mutation further underscores our commitment to developing transformative therapies for patients.

Key Business and Clinical Highlights

PKR Program in Sickle Cell Disease (SCD):

CPB/p300 Program in Prostate Cancer:

IDH1 Program in AML and Glioma:

Corporate:

Upcoming Milestones

Upcoming Investor Events

Financial Results

About Forma Therapeutics

Forma Therapeutics is a clinical-stage biopharmaceutical company focused on the research, development and commercialization of novel therapeutics to transform the lives of patients with rare hematologic diseases and cancers. Our R&D engine combines deep biology insight, chemistry expertise and clinical development capabilities to create drug candidates with differentiated mechanisms of action focused on indications with high unmet need. Our work has generated a broad proprietary portfolio of programs with the potential to provide profound patient benefit. For more information, please visit http://www.FormaTherapeutics.com or follow us on Twitter @FORMAInc and LinkedIn.

Forward-looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, express or implied statements regarding the companys beliefs and expectations regarding its: business plans and objectives; future plans for FT-4202 and FT-7051, including expectations regarding timing and success of the current ongoing clinical trials, therapeutic potential and clinical benefits thereof, and upcoming milestones for the companys other product candidates; growth as a company and the anticipated contribution of the members of our board of directors to our operations and progress; presentation of additional data at upcoming scientific conferences, and other preclinical data in 2020; the potential commercial and collaboration opportunities, including potential future collaborators and parties, as well as value and market, for our product candidates; uses of capital, expenses and other 2020 financial results or in the future, and the potential impact of COVID-19 on patient retention, strategy, future operations, clinical trials or IND submissions. The words may, will, could, would, should, expect, plan, anticipate, intend, believe, estimate, predict, project, potential, continue, target and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words.

Any forward-looking statements in this press release are based on managements current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release, including, without limitation, those risks and uncertainties associated with: the impact of the COVID-19 pandemic on the companys business, operations, strategy, goals and anticipated milestones; the therapeutic potential of FT-4202, and the timing associated with the initiation or continuation of any of FT-4202 trials; the initiation of our phase I clinical trial of FT-7051; Formas ability to execute on its strategy; positive results from a clinical study may not necessarily be predictive of the results of future or ongoing clinical studies; regulatory developments in the United States and foreign countries; Formas ability to fund operations; Formas ability to identify satisfactory collaboration opportunities, as well as those risks and uncertainties set forth more fully under the caption "Risk Factors" in the final prospectus dated June 22, 2020 and filed pursuant to Rule 424(b) under the Securities Act of 1933, as amended, with the United States Securities and Exchange Commission (SEC) and elsewhere in Formas filings and reports with the SEC. Forma disclaims any obligation to publicly update or revise any such statements to reflect any change in expectations or in events, conditions or circumstances on which any such statements may be based, or that may affect the likelihood that actual results will differ from those set forth in the forward-looking statements. Any forward-looking statements contained in this press release represent Formas views only as of the date hereof and should not be relied upon as representing its views as of any subsequent date. Forma explicitly disclaims any obligation to update any forward-looking statements.

2020

2019

2020

2019

$ -

$ 3,377

$ -

$ 93,113

24,780

27,558

68,501

84,273

7,460

7,025

22,841

17,631

-

545

63

5,620

32,240

35,128

91,405

107,524

(32,240)

(31,751)

(91,405)

(14,411)

818

766

23,050

3,057

(31,422)

(30,985)

(68,355)

(11,354)

(3,806)

-

(26,529)

(1,217)

$ (27,616)

$ (30,985)

$ (41,826)

$ (10,137)

-

(607)

(3,736)

(2,395)

-

-

-

(11,347)

-

(60)

-

(60)

$ (27,616)

$ (45,562)

(8)

-

$ (27,624)

$ (45,562)

$ (31,652)

$ (23,939)

(198)

(515)

$ (31,850)

$ (24,454)

$ (0.67)

$ (2.74)

$ (0.67)

$ (2.74)

$ (12.42)

$ (9.40)

$ (12.50)

$ (9.60)

41,088,261

16,616,143

41,088,924

16,616,143

2,547,924

Read the original here:
Forma Therapeutics Reports Third Quarter 2020 Financial Results and Provides Business Update - Galveston County Daily News

Adipose Tissue-Derived Stem Cells (ADSCS) Market Expected to Witness High Growth over the Forecast 2027 – BCFocus

Data Bridge Market Research has recently published the Global research Report TitledAdipose Tissue-Derived Stem Cells (ADSCS) Market.

TheAdipose Tissue-Derived Stem Cells (ADSCS) Marketreport gives acquaintance about all the recent developments, product launches, joint ventures, mergers and acquisitions by several key players and brands while also giving a synopsis of market definition, classifications, and market trends. It lends a hand to companies to take decisive actions to deal with threats in a niche market. This market research report also provides thorough information about target markets or customers. Global Adipose Tissue-Derived Stem Cells (ADSCS) Market report is a sure-fire solution that businesses can adopt to thrive in this swiftly changing marketplace. For outstanding business growth, companies must take upmarket research report service which has become enough vital in todays market place.

Adipose tissue-derived stem cells (ADSCS) market is expected to gain market growth in the forecast period of 2020 to 2027. Data Bridge Market Research analyses the market to account grow at a CAGR of 6.1% in the above-mentioned forecast period. The accelerating application of adipose tissue-derived stem cells (ADSCS) in the regenerative medicines research, development of cell linage, tissue engendering, bone and cartilage regeneration are driving the exponential growth of adipose tissue-derived stem cells (ADSCS) market during the forecast period of 2020 to 2027.

This report examines all the key factors influencing the growth of Adipose Tissue-Derived Stem Cells (ADSCS) market, including demand-supply scenario, pricing structure, profit margins, production and value chain analysis. Regional assessment of Adipose Tissue-Derived Stem Cells (ADSCS) market unlocks a plethora of untapped opportunities in regional and domestic marketplaces. Detailed company profiling enables users to evaluate company shares analysis, emerging product lines, the scope of NPD in new markets, pricing strategies, innovation possibilities and much more.

Get Free Sample Copy of the Report to Understand the Structure of the Complete Report @ https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-adipose-tissue-derived-stem-cells-adscs-market

The Global Adipose Tissue-Derived Stem Cells (ADSCS) Market research report assembles data collected from different regulatory organizations to assess the growth of the segments. In addition, the study also appraises the global Adipose Tissue-Derived Stem Cells (ADSCS) market on the basis of topography. It reviews the macro- and microeconomic features influencing the growth of the Adipose Tissue-Derived Stem Cells (ADSCS) Market in each region. Various methodological tools are used to analyze the growth of the worldwide Adipose Tissue-Derived Stem Cells (ADSCS) market.

Prominent Key Players Covered in the report:

Antria Inc., CELGENE CORPORATION, pluristem, Tissue Genesis, Cytori Therapeutics Inc., PRECIGEN, Mesoblast Ltd, CORESTEM, Inc, among other domestic and global players.

Major Regions as Follows:

North America (USA, Canada and Mexico)

Europe (Germany, France, the United Kingdom, Netherlands, Russia , Italy and Rest of Europe)

Asia-Pacific (China, Japan, Australia, New Zealand, South Korea, India and Southeast Asia)

South America (Brazil, Argentina, Colombia, rest of countries etc.)

Middle East and Africa (Saudi Arabia, United Arab Emirates, Israel, Egypt, Nigeria and South Africa)

A complete value chain of the global Adipose Tissue-Derived Stem Cells (ADSCS) market is presented in the research report. It is associated with the review of the downstream and upstream components of the Adipose Tissue-Derived Stem Cells (ADSCS) Market. The market is bifurcated on the basis of the categories of products and customer application segments. The market analysis demonstrates the expansion of each segment of the global Adipose Tissue-Derived Stem Cells (ADSCS) market. The research report assists the user in taking a decisive step that will be a milestone in developing and expanding their businesses in the global Adipose Tissue-Derived Stem Cells (ADSCS) market.

Get Table Of Contents of This Premium Research For Free: https://www.databridgemarketresearch.com/toc/?dbmr=global-adipose-tissue-derived-stem-cells-adscs-market

How Does This Market Insights Help?

Key Pointers Covered in the Adipose Tissue-Derived Stem Cells (ADSCS) Market Industry Trends and Forecast

Reasons to Purchase this Report

Request Free Sample PDF (including COVID19 Impact Analysis) of Adipose Tissue-Derived Stem Cells (ADSCS) MarketReport@https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-adipose-tissue-derived-stem-cells-adscs-market

Market Dynamics:The Adipose Tissue-Derived Stem Cells (ADSCS) report also demonstrates the scope of the various commercial possibilities over the coming years and the positive revenue forecasts in the years ahead. It also studies the key markets and mentions the various regions i.e. the geographical spread of the industry.

TABLE OF CONTENTS

Part 01:Executive Summary

Part 02:Scope of the Report

Part 03:Research Methodology

Part 04:Market Landscape

Part 05:Pipeline Analysis

Pipeline Analysis

Part 06:Market Sizing

Market Definition

Market Sizing

Market Size And Forecast

Part 07:Five Forces Analysis

Bargaining Power Of Buyers

Bargaining Power Of Suppliers

Threat Of New Entrants

Threat Of Substitutes

Threat Of Rivalry

Market Condition

Part 08:Market Segmentation

Segmentation

Comparison

Market Opportunity

Part 09:Customer Landscape

Part 10:Regional Landscape

Part 11:Decision Framework

Part 12:Drivers and Challenges

Market Drivers

Market Challenges

Part 13:Market Trends

Part 14:Vendor Landscape

Part 15:Vendor Analysis

Vendors Covered

Vendor Classification

Market Positioning Of Vendors

Part 16:Appendix

In conclusion, the Adipose Tissue-Derived Stem Cells (ADSCS) Market report is a reliable source for accessing the research data that is projected to exponentially accelerate your business. The report givesinformation such as economic scenarios, benefits, limits, trends, market growth rates, and figures. SWOT analysis is also incorporated in the report along with speculation attainability investigation and venture return investigation.

Get Enquiry About This Comprehensive Report: https://www.databridgemarketresearch.com/inquire-before-buying/?dbmr=global-adipose-tissue-derived-stem-cells-adscs-market

Thank you for reading this article. You can also get chapter-wise sections or region-wise report coverage for North America, Europe, Asia Pacific, Latin America, and Middle East & Africa.

Customization of the Report:

Data Bridge Market Research also provides customization options to tailor the reports as per client requirements. This report can be personalized to cater to your research needs. Feel free to get in touch with our sales team, who will ensure that you get a report as per your needs.

About Data Bridge Market Research:

Data Bridge Market Researchis a versatile market research and consulting firm with over 500 analysts working in different industries. We have catered more than 40% of the fortune 500 companies globally and have a network of more than 5000+ clientele around the globe. Our coverage of industries include Medical Devices, Pharmaceuticals, Biotechnology, Semiconductors, Machinery, Information and Communication Technology, Automobiles and Automotive, Chemical and Material, Packaging, Food and Beverages, Cosmetics, Specialty Chemicals, Fast Moving Consumer Goods, Robotics, among many others.

Data Bridge adepts in creating satisfied clients who reckon upon our services and rely on our hard work with certitude.We are content with our glorious 99.9 % client satisfying rate.

Contact Us

Data Bridge Market Research

US: +1 888 387 2818

UK: +44 208 089 1725

Hong Kong: +852 8192 7475

Mail:Corporatesales@databridgemarketresearch.com

Original post:
Adipose Tissue-Derived Stem Cells (ADSCS) Market Expected to Witness High Growth over the Forecast 2027 - BCFocus

CODA Biotherapeutics Receives Grant from the National Institute of Neurological Disorders and Stroke (NINDS) of the National Institutes of Health…

SOUTH SAN FRANCISCO, Calif., Nov. 10, 2020 /PRNewswire/ -- CODA Biotherapeutics, Inc., a preclinical-stage biopharmaceutical company developing a gene therapy-mediated chemogenetic platform to treat neurological disorders and diseases with an initial focus on neuropathic pain and epilepsy, today announced it has been awarded a Small Business Innovation Research (SBIR) grant from the National Institute of Neurological Disorders and Stroke (NINDS) of the National Institutes of Health (NIH). As part of theNIH Helping to End Addiction Long-term InitiativeSM, or NIH HEAL InitiativeSM, the funding of $670,000 over two years will be used to support CODA's plans to evaluate and advance the Company's unique receptor-ligand pairs toward the clinic for the treatment of neuropathic pain. Orion P. Keifer, Jr. M.D., Ph.D., Vice President, Discovery and Translation at CODA, will serve as the program's principal investigator.

"We are unwavering in our commitment to developing novel chemogenetic therapies for the treatment of neurological disorders and diseases like neuropathic pain for which current treatment options have significant limitations," said Michael Narachi, President and Chief Executive Officer, CODA. "We are honored to receive this grant from NINDS, as this funding will help advance our chemogenetic platform toward human clinical trials where we hope to demonstrate transformative results for patients."

CODA Biotherapeutics is developing a paradigm-shifting gene therapy approach for neuropathic pain by deploying a chemogenetic strategy for treating neuropathic pain sensations at their origin. The Company's innovative treatment aims to modulate specific neuronal circuits where pain arises via adeno-associated virus-mediated delivery of an engineered inhibitory receptor. The receptor is designed to be quiescent in the transduced cells but will specifically and dose-dependently inhibit neurons when exposed to a novel, orally bioavailable small-molecule agonist. CODA expects this treatment will produce substantially improved and durable pain relief while potentially avoiding off-target/adverse effects of currently available treatments.

The NINDS SBIR/Small Business Technology Transfer (STTR) program funds small business concerns to conduct innovative neuroscience research and/or development that has both the potential for commercialization and public health benefit.

In addition, CODA was recently selected to collaborate with NIH's National Center for Advancing Translational Science (NCATS), also as part of the NIH HEAL initiative. CODA will partner with the Stem Cell Translation Laboratory led by Ilyas Singec, M.D., Ph.D., in the NCATS Division of Preclinical Innovation (DPI) in developing induced pluripotent stem cell (iPSC)-derived human Ab sensory neurons for the identification and characterization of novel neuropathic pain therapies. The joint NCATS/CODA collaboration will leverage expertise and technologies available at Dr. Singec's lab to jointly develop protocols for generating iPSC-derived A primary sensory neurons, which CODA will then use for the identification and evaluation of inhibitory chemogenetic receptors for the treatment of neuropathic pain. G. Steven Dodson, Ph.D., Vice President of Pharmacology and Early Development at CODA will serve as lead collaborator.

"Ab neurons are a key cell type for the evaluation of our receptor-ligand combinations and their development should advance the translational understanding of how our approach may impact pain states in patients. Through this partnership, CODA will collaborate with and gain access to the scientific capabilities, expertise, state-of-the-art technologies, and resources of the NCATS DPI to develop iPSC-derived human Ab sensory neurons, which will help us progress our neuropathic pain therapies toward the clinic," added Mr. Narachi.

About Neuropathic Pain According to a study published in the Journal of Pain Research, 10 percent of the U.S. population suffers from neuropathic pain an estimated 30 million Americans. Neuropathic pain is caused by damage or disease of the sensory system, leading to chronic debilitation and loss of quality of life. Current pharmacological therapies for chronic neuropathic pain, such as opioids, anticonvulsants, and tricyclic anti-depressants, are not always effective and can have side effects, including the potential for addiction.

About the CODA Platform CODA's chemogenetic platform aims to reverse the aberrant neuronal activity underlying many neurological disorders. With chemogenetics, dysfunctional neurons are modified using optimized adeno-associated virus (AAV) vectors delivered directly to them by standard-of-care neurosurgical procedures. The AAV vectors encode ligand-gated ion channels (chemogenetic receptors) that are highly responsive to specific proprietary small molecule therapeutics but are otherwise inactive. The activity of these receptors, and thus the aberrant activity of the modified neurons, is controlled in a selective and tunable manner through administration of the small molecule to generate therapeutic benefit with minimal side effects.

About CODA Biotherapeutics CODA Biotherapeutics, Inc., is a preclinical-stage biopharmaceutical company developing an innovative gene therapy platform to treat neurological disorders and diseases. The Company is creating the ability to control neurons with its revolutionary chemogenetics-based technology. CODA is located in South San Francisco, CA. For more information, please visit http://www.codabiotherapeutics.com.

View original content to download multimedia:http://www.prnewswire.com/news-releases/coda-biotherapeutics-receives-grant-from-the-national-institute-of-neurological-disorders-and-stroke-ninds-of-the-national-institutes-of-health-nih-to-help-advance-its-next-generation-gene-therapy-mediated-chemogenetic-platfor-301168028.html

SOURCE CODA Biotherapeutics, Inc.

View original post here:
CODA Biotherapeutics Receives Grant from the National Institute of Neurological Disorders and Stroke (NINDS) of the National Institutes of Health...

Marker Therapeutics Reports Third Quarter 2020 Operating and Financial Results – PRNewswire

HOUSTON, Nov. 9, 2020 /PRNewswire/ -- Marker Therapeutics, Inc.(Nasdaq:MRKR), a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications, today provided a corporate update and reported financial results for the third quarter ended September 30, 2020.

"This quarter, our Company reached a significant milestone by initiating our first Marker-sponsored studya Phase 2 trial of zelenoleucel or MT-401, our lead MultiTAA-specific T cell product candidate for the treatment of post-transplant acute myeloid leukemia," said Peter L. Hoang, President & CEO of Marker Therapeutics. "We have enrolled the first patient in the safety lead-in portion of the trial, and are in the process of scheduling the donor in order to manufacture the product."

Continued Mr. Hoang: "During this unprecedented time, we have made significant progress by enrolling additional clinical sites for our AML trial, advancing our manufacturing process, reducing production time by 50% and improving the potency of our MT-401 product, and entering the final phase of the construction of our new in-house cGMP manufacturing facility. I am extremely proud of the dedication and resolve that our team has shown during these challenging months. I want to acknowledge their hard work across the organization that went into achieving these milestones."

PROGRAM UPDATES

MT-401: Multi-Antigen Targeted (MultiTAA)-Specific T Cell Product Candidate for AML

Phase 2 AML Trial The Company initiated the safety lead-in portion of its Phase 2 study of zelenoleucel (MT-401) in patients with acute myeloid leukemia (AML) following an allogeneic stem cell transplant in both the adjuvant and active disease settings. The Company anticipates treating the first patient by Q1 2021. The safety lead-in is expected to enroll a total of six patients: three of which will be treated with MT-401 manufactured with a legacy reagent, and the remaining three to be treated with study drug manufactured with a new reagent from an alternate supplier.

Marker has activated four clinical sites and is in the start-up phase with additional clinical sites to enroll patients for the safety lead-in portion of the AML trial. The Company has also received commitments from additional clinical sites to participate in the Phase 2 AML trial following the safety lead-in phase and anticipates activating a total of approximately 20 sites.

The study remains on partial clinical hold pending the review of final data and subsequent acceptance of certificates of analysis for the new reagent by the U.S. FDA. The Company received the remaining reagent from the alternate supplier in Q3 2020 and is currently conducting the comparability analyses between the previous and new reagents, as required by FDA. Marker intends to submit all required data to FDA by Q1 2021 to enable removal of the partial clinical hold.

Over the past year, the Company has continued to streamline and simplify the MT-401 manufacturing process. The technical improvements include a 50% reduction in manufacturing time, a 95% reduction in the number of required operator interventions, and significant improvement in the consistency and reproducibility of the manufacturing process, while yielding a significant increase in the number of T cells available for patient administration. The Company expects the new process to yield a measurably improved product, with superior T cell phenotype and antigen specificity as compared to the original process. The new process improvements have been updated in the CMC section of the IND and will be used for all patients in the Marker AML clinical trial.

BUSINESS UPDATES

THIRD QUARTER 2020 FINANCIAL RESULTS

Cash Position and Guidance:At September 30, 2020, Marker had cash and cash equivalents of $27.0 million. The Company raised $2.2 million through the previously executed $30 million common stock purchase agreement with Aspire Capital Fund, LLC. The remaining $27.8 million available to Marker from Aspire Capital along with current cash available, funds operations into Q1 2022.

R&D Expenses:Research and development expenses were$4.8 million for the quarter endedSeptember 30, 2020, compared to$3.1 million for the quarter ended September 30, 2019.

G&A Expenses:General and administrative expenses were$2.6 million for the quarter endedSeptember 30, 2020, compared to $2.5 million for the quarter ended September 30, 2019.

Net Loss:Marker reported a net loss of$7.4 millionfor the quarter endedSeptember 30, 2020, compared to a net loss of$5.5 million for the quarter ended September 30, 2019.

Conference Call and Webcast

The Company will host a webcast and conference call to discuss its third quarter 2020 financial results and provide a corporate update today at 5:00 PM EST.

The webcast will be accessible in theInvestorssection of the Company's website at markertherapeutics.com. Individuals can participate in the conference call by dialing 877-407-8913 (domestic) or 201-689-8201 (international) and referring to the "Marker Therapeutics Third Quarter 2020 Earnings Call."

The archived webcast will be available for replay on the Marker website following the event.

About Marker Therapeutics, Inc. Marker Therapeutics, Inc. is a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. Marker's cell therapy technology is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor associated antigens (i.e. tumor targets) and kill tumor cells expressing those targets. This population of T cells is designed to attack multiple tumor targets following infusion into patients and to activate the patient's immune system to produce broad spectrum anti-tumor activity. Because Marker does not genetically engineer its T cell therapies, we believe that our product candidates will be easier and less expensive to manufacture, with reduced toxicities, compared to current engineered CAR-T and TCR-based approaches, and may provide patients with meaningful clinical benefit. As a result, Marker believes its portfolio of T cell therapies has a compelling product profile, as compared to current gene-modified CAR-T and TCR-based therapies.

To receive future press releases via email, please visit:https://www.markertherapeutics.com/email-alerts

Forward-Looking Statement Disclaimer This release contains forward-looking statements for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Statements in this news release concerning the Company's expectations, plans, business outlook or future performance, and any other statements concerning assumptions made or expectations as to any future events, conditions, performance or other matters, are "forward-looking statements." Forward-looking statements include statements regarding our intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things: our research, development and regulatory activities and expectations relating to our non-engineered multi-tumor antigen specific T cell therapies; the effectiveness of these programs or the possible range of application and potential curative effects and safety in the treatment of diseases; the impact of the COVID-19 pandemic; the timing, conduct and success of our clinical trials, as well as clinical trials conducted by our collaborators; our manufacturing processes and our ability to use our in-house manufacturing facility to support clinical and commercial demand. Forward-looking statements are by their nature subject to risks, uncertainties and other factors which could cause actual results to differ materially from those stated in such statements. Such risks, uncertainties and factors include, but are not limited to the risks set forth in the Company's most recent Form 10-K, 10-Q and other SEC filings which are available through EDGAR at http://www.sec.gov. Such risks and uncertainties may be amplified by the COVID-19 pandemic and its impact on our business and the global economy. The Company assumes no obligation to update our forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release.

Marker Therapeutics, Inc.

Condensed Consolidated Balance Sheets

September 30,

December 31,

2020

2019

(Unaudited)

(Audited)

ASSETS

Current assets:

Cash and cash equivalents

$ 26,956,737

$ 43,903,949

Prepaid expenses and deposits

2,367,145

1,526,442

Interest receivable

135

56,189

Other receivable

1,000,000

-

Total current assets

30,324,017

45,486,580

Non-current assets:

Property, plant and equipment, net

2,629,628

417,528

Construction in progress

4,557,581

-

Right-of-use assets, net

11,059,962

455,174

Total non-current assets

18,247,171

872,702

Total assets

$ 48,571,188

$ 46,359,282

LIABILITIES AND STOCKHOLDERS' EQUITY

Current liabilities:

Accounts payable and accrued liabilities

$ 5,746,149

$ 1,757,680

Lease liability

278,333

204,132

Warrant liability

-

31,000

Total current liabilities

6,024,482

1,992,812

Non-current liabilities:

Lease liability, net of current portion

11,948,781

280,247

Total non-current liabilities

11,948,781

280,247

Total liabilities

17,973,263

2,273,059

Commitments and contingencies

-

-

Stockholders' equity:

Preferred stock - $0.001 par value, 5 million shares authorized and 0 shares issued and outstanding at September 30, 2020 and December 31, 2019, respectively

-

-

Common stock, $0.001 par value, 150 million shares authorized, 48.0 million and 45.7 million shares issued and outstanding as of September 30, 2020 and December 31, 2019, respectively

48,025

45,728

Additional paid-in capital

378,282,157

371,573,909

Go here to see the original:
Marker Therapeutics Reports Third Quarter 2020 Operating and Financial Results - PRNewswire

Brain Development and Disorder Research Receives $1.5 Million NSF Boost – USC Viterbi School of Engineering

Megan McCain, Giorgia Quadrato and Leonardo Morsut have been awarded a four year National Science Foundation grant to develop better organoids, to help us understand human brain development and disease.

A 15-day-old brain organoid: Department of Biomedical Engineering researchers are partnering with Keck School of Medicine of USC to improve the creation of these materials, which can help us better understand brain development and disorders.Image/ Giorgia Quadrato

The human brain is an incredibly complex organ to study in its living tissue form. Researchers cannot experiment on human tissue directly, and animal models are often too different to human physiology to be effective.

For this reason, in the last decade, neurological research has been increasingly turning to brain-on-a-chip organoid models to give researchers living examples to demonstrate brain development, and how to effectively treat brain diseases and disorders. Organoids are grown out of stem cells into new cell clusters that mimic the structure of and features of a whole organ, such as the brain.

Co-principal investigator Megan McCain from the USC Viterbi Department of Biomedical Engineering will partner with fellow co-principal investigators Giorgia Quadrato and Leonardo Morsut in the Department of Stem Cell Biology and Regenerative Medicine at the Keck School of Medicine of USC on a four year, $1.5m NSF-funded project to vastly improve the process of developing brain organoids. The project aims to make the end products more consistent and reliable as tools for brain researchers.

McCain is the Chonette Early Career Chair and assistant professor of biomedical engineering at USC Viterbi. She said that one of the biggest hurdles in the current process of organoid creation was their lack of uniformity.

Researchers start with a small group of human stem cells, and then give them some chemical cues to direct their development into brain tissue, but ultimately, the cells are mostly left to their own devices, so they often grow very randomly, McCain said. They divide and differentiate into other cell types in a somewhat haphazard process. So if you make ten organoids, all ten of them will look slightly different.

A brain organoid in a fluidic device from the labs of Megan McCain and Giorgia Quadrato.

McCain said it was this issue that could be detrimental to the accuracy of using organoids in certain types of research, such as the testing of therapeutics and how the brain responds to these drugs, and that organoids needed to be more uniform and reproducible in order to be more effective tools.

Drug testing with organoids today is very challenging because it is hard to separate the effect of the drug from the inherent variability of the organoids themselves, McCain said.

Morsut said that his part of the project involves developing synthetic molecular tools to simplify the analysis of what happens during the formation of brain organoids in a laboratory setting.

The normal molecules that are used by the cells to self-organize, as well as to make decisions, are linked in very complex networks, and we need artificial tools to tease apart the contributions of these different components, Morsut said. The challengeand the exciting partis to use these tools to explain the remarkable phenomenon of self-organization.

McCain said her lab will focus on the device sidethe organ-on-chipand make microfluidic components for growing and studying organoids under more defined conditions.

This will likely improve reproducibility and possibly organoid maturity, which is another major bottleneck, McCain said.

In order to do this, McCains lab will be repurposing a microfluidic device that they previously used to help explanted zebrafish hearts to remain alive longer and regenerate, while also live-imaging the process.

The device, when applied to brain organoids, will constrain the cells in chambers where the team can run experiments through them in a more controlled way, to see if this improves the consistency of the end product.

And we will also be able to image and monitor their reproducibility by putting them in this little device where theyre all growing in the same configuration, McCain said.

Quadrato, an expert in brain organoids, said she was excited about the collaboration, because a multidisciplinary approach was needed to improve the relevance of current organoids.

One way to improve brain organoid-to-organoid reproducibility is to expose them to small molecules to direct differentiation of the stem cells, Quadrato said.

She said that these small molecules unfortunately sometimes have problematic side effects, such as impairing the survival of other non-neural cell types, or skewing tests of potential treatments for brain diseases and disorders.

In our proposal, we suggest an alternative strategy to increase brain organoid reproducibility that does not cause these side effects, and therefore can be used to create organoids to accurately model disease, Quadrato said.

Further information about the project is available from the National Science Foundation.

View post:
Brain Development and Disorder Research Receives $1.5 Million NSF Boost - USC Viterbi School of Engineering

Election 2020: Californias ballot initiative system isnt working. – Vox.com

Finding the best ways to do good.

I live in California. And three weeks before the election, the people in my quarantine bubble sat down in our living room for a nine-hour research project: figuring out how to vote.

Not for our elected representatives or for president, but on kidney dialysis regulations and stem-cell medical research funding and whether to uphold a law passed by the legislature replacing cash bail with a risk assessment system and nine more propositions after those. My ballot was six pages long, many of them on issues Id never thought about before and, after a few frustrating hours figuring out how to vote, will never think about again.

Direct democracy can be a profound and important tool for political change, and 2020 had many examples of that. In several states, voters decriminalized drugs from marijuana to mushrooms sending a powerful message to lawmakers that their constituents are done with the war on drugs. Ive written in past years that voters are way ahead of state legislatures on banning animal cruelty. Americas electoral system definitely benefits from a place for voters to directly weigh in on issues. (My colleague Sigal Samuel has a rundown of the ballot initiatives that we should cheer in todays edition of the Future Perfect newsletter. Subscribe!)

But what it doesnt benefit from is a system like Californias, where ballots get padded out and weighted down with unclearly written ballot propositions on a dozen niche issues. Many people have been frustrated by these problems on their ballots, but California where voters have been asked to simultaneously entertain abolishing and expediting the death penalty, to weigh dueling propositions about plastic bags, to advise the state legislature to overturn US Supreme Court decisions (it cannot do that), and now, on two different occasions, to weigh in on the proper running of dialysis clinics leads the pack.

A system that funnels lots of issues, both big and small, directly to the voters leads to bad policy judgments, because under-informed voters dont have time to research and form opinions on all the issues. It leads to a handicapped legislature that cant do its job, because large sections of state law are untouchable. (In California, for instance, the legislature has to send many propositions to voters because other propositions have prohibited them from legislating directly.) When a voter-approved initiative is unclearly worded, it can cause years of uncertainty because the issue cant easily be sent back to the voters to adjust the wording.

But just because how we run ballot propositions today is a problem doesnt mean we have to give them up altogether. There is a way we can make direct democracy work.

Lets say that you dislike the work your state legislature is doing. In 26 US states and Washington, DC, you have the power to ask voters to pass laws themselves through a ballot initiative.

There are, broadly, three categories of ballot initiatives available in the states that have a citizen initiative process. In the first, citizens draw up a proposed law and put it on the ballot. If other citizens approve it, it becomes a law. In the second, citizens who disapprove of a law the legislature passed put it on the ballot to try to repeal it (called a veto referendum). In the third, citizens propose, and vote on, a change to the state constitution.

Some states only allow some of these types of initiatives, and some dont allow citizen initiatives at all. Maryland and New Mexico, for example, only allow veto referendums; Utah, Wyoming, Washington, Maine, Alaska, and Idaho allow citizens to put forth initiatives, but not constitutional amendments. Illinois, Mississippi, and Florida allow constitutional amendments but not initiatives.

The details of the process to put a new law, a veto referendum, or a constitutional amendment on the ballot varies from state to state, but in general, proponents file their proposed initiative with the state and then start collecting signatures for it. If they collect enough signatures, it goes on the ballot for the next statewide election. If it wins over enough voters at the election, it becomes a law.

Lots of important work has gotten done through ballot initiatives. But in many ways, laws passed via initiative are more problematic than laws passed by the legislature. Because they are not written by professional legislators, they are often unclearly written; many voters report being confused about what ballot initiatives they voted on will do. Many ballot measures are misleadingly structured so that a no vote represents a big, confusing change to the law, while a yes vote does nothing. There is fierce political fighting about initiatives are summarized on the ballot a process that is supposed to be apolitical, but sometimes isnt.

And while initiatives were meant to empower grassroots political movements, the system to put an initiative on the ballot is much easier for large lobbying groups to navigate, and special interest groups drive many initiatives.

In some states, like California, the sheer number of initiatives is starting to get out of hand, which worsens all of the other problems with ballot initiatives, as its easier for voters to see through one misleading proposition than through 10.

Every state does direct democracy in a different way.

But California reliably has one of the longest ballots. In 2016, there were 17 statewide initiatives. The voter guide mailed to all voters to explain them was 224 pages long.

In 2020, the threshold for initiatives to make the ballot was substantially higher (the threshold is set based on turnout in the most recent governors race, and 2018 turnout set records) and there werent as many. But voters still weighed in on bonds to pay for stem cell research, property tax changes, a repeal to the state ban on affirmative action, restoring voting rights for convicted felons, allowing 17-year-olds who will be 18 in November to vote in primaries, more property tax changes, changes to criminal sentencing, allowing rent control in more parts of the state, labor policies for ride-hailing apps, dialysis clinic regulations, a new data privacy law, and abolishing cash bail.

Those were just the statewide initiatives; voters also considered many city and countywide local initiatives. Thats 12 statewide initiatives, more than anywhere else in the country (though Colorado voters came close, with 11.)

California also had by far the most spending aimed at changing minds on ballot initiatives: $708 million in contributions, compared to $121 million in the next most-contested state. Across all 50 states, 120 ballot measures were decided on Election Day.

Californias initiative process permits all three types of resolutions (initiatives to create a new state law, initiatives to veto a state law passed through the legislative process, and initiatives to amend the constitution) and makes it much easier than many states to put an initiative on the ballot requiring just 5 percent of the number of voters who voted in the gubernatorial race in the most recent election to put an initiative on the ballot. Many states require 10 percent of the number of votes cast for governor and many states have competitive elections for governors.

Californias gubernatorial races are almost never competitive and often have very low turnout, which depresses the signature requirement further. In 2016, only 365,880 signatures were needed (in a state with 40 million people and 18 million registered voters) to add an initiative to the ballot. (High 2018 turnout raised the bar somewhat, but as a percentage of total population, its still one of Americas lowest thresholds.)

Finally, its not just easier for laws to make it onto the ballot; its also easier for them to pass. In many states amending the constitution requires a supermajority. In Florida, for example, which amended its constitution this week to raise the minimum wage, a 60 percent majority is required. In California, propositions including those amending the state constitution pass if they get more than 50 percent of the vote.

California was one of the first states that allowed citizen-driven ballot initiatives, and at first, ballot initiatives were sparse. As collecting signatures became easier, the number of California propositions has spiked especially in the last few decades. As a result, the initiative system has grown quite unwieldy and crude in ways that have perverted the initial vision, historian William Deverell at the University of Southern California said this fall.

For all of the drawbacks of ballot initiatives, the variety of different approaches to propositions in different states is a great thing one of the best examples of the state systems function as laboratories of democracy.

We now have some results from those laboratories of democracy, and they suggest that the initiative system works best when there are a manageable number of initiatives on the ballot at election time. Voter participation is higher, and voters are more able to focus their attention on a handful of meaningful, high-value issues: Should we legalize marijuana? Should we reenfranchise people who have been convicted of a crime and served their sentence? Should we change how our state votes?

When voters are snowed under with nearly a dozen propositions, including many on highly specific niche issues like kidney dialysis regulation that theyre unequipped to evaluate, participation drops, and the results become more strongly predicted by which side spent the most money probably because if voters dont have time to look things up, theyre more likely to go with what they saw on TV. The impressive successes of ballot initiatives against the war on drugs this year should have governments in every state thinking about how they can best use ballot initiatives to their full potential.

For the 14 states that dont allow any ballot initiatives, that might mean rethinking that. But for the states that allow ballot initiatives with a very low threshold, and see low participation and high voter confusion as a result, it means rethinking that, too. Promising proposals include raising the signature threshold, capping the number of propositions on the ballot, and restricting counter-propositions conflicting laws on the ballot at the same time.

Direct democracy is a part of our system because of a belief that voters deserve a direct say in how their state is run. The best implementation gives voters a few highly meaningful choices well worth their time. If we cant manage that, were not empowering voters were burdening them.

Sign up for the Future Perfect newsletter. Twice a week, youll get a roundup of ideas and solutions for tackling our biggest challenges: improving public health, decreasing human and animal suffering, easing catastrophic risks, and to put it simply getting better at doing good.

Will you help keep Vox free for all?

Millions of people rely on Vox to understand how the policy decisions made in Washington, from health care to unemployment to housing, could impact their lives. Our work is well-sourced, research-driven, and in-depth. And that kind of work takes resources. Even after the economy recovers, advertising alone will never be enough to support it. If you have already made a contribution to Vox, thank you. If you havent, help us keep our journalism free for everyone by making a financial contribution today, from as little as $3.

Read the original:
Election 2020: Californias ballot initiative system isnt working. - Vox.com

Many Initiatives Still Too Close to Call in California – Courthouse News Service

SACRAMENTO, Calif. (CN) A record 22 million Californians registered to vote ahead of the November general election. While the allure of choosing the next occupant of the White House no doubt spurred many of them to the ballot box, they also had a list of initiatives to decide ranging from whether the state should go to a split-roll property tax scheme to ending the money bail system.

The bid to end cash bail failed, but heres a look at how some of the other propositions are faring even as the vote count continues:

Proposition 15

Ignoring pleas for budget relief from Californias cash-strapped cities and Governor Gavin Newsom, voters are on the verge of rejecting a bid to amend the states landmark tax code and put the squeeze on commercial landlords.

With over 75% of the estimated total vote counted, 52% have voted no on Proposition 15 the so-called split-roll bid. The proponents dreams of raising up to $11.5 billion in new tax revenues for schools and cities is on the ropes, as the measure faces a 426,000 vote-deficit as of Friday.

If the result holds, it would be further proof of the popularity and resiliency of a voter-approved tax scheme that is credited with preventing runaway tax bills for property owners in the Golden State for decades.

Seeking to make taxes more predictable and stable, 63% of Californians voted in 1978 to amend the state constitution in order to slow tax increases for both commercial and residential property. Considered by many as the third rail of California politics, the system caps annual tax increase on both commercial and residential properties.

The tax code has remained largely unchanged despite the fact its long been a target of some of the states most influential labor unions. Former lawmakers and governors even during previous economic downturns have hardly dared to challenge the tax code, wary of its reputation.

But with the state facing a record $54 billion Covid-induced deficit, proponents have been trying to convince voters they could unearth a giant new revenue stream by raising taxes on commercial properties valued above $3 million. The supporters amassed a deep and influential bench featuring Newsom, former Vice President Joe Biden, Facebook CEO Mark Zuckerberg and many of the states largest labor unions.

Leading the fight against the tax reform are a collection of business and agricultural groups, as well as the Howard Jarvis Taxpayers Association named after the author of the original ballot measure. They cast Proposition 15 as the largest property tax increase in California history and claimed it would send commercial rents and the cost of consumer goods skyrocketing.

In the run up to the election, the sides combined to raise a staggering $139 million on Proposition 15.

To pull off a comeback in the coming days or potentially weeks, the proponents are hoping to glean more support from many of the states coastal counties in the final batches of votes.The proposition has had success thus far in counties like Los Angeles (53-47%), San Francisco (71-29%), Santa Clara (56-44%), Alameda (66-34%) and Marin (63-37%).

Proponents can find a glimmer of hope in the fact that according to the Secretary of States latest estimates, there are still nearly 1 million outstanding ballots in Los Angeles and Alameda alone. Statewide, there are an estimated 4.5 million ballots left to be counted as of Thursday evening.

Support fades inland however as voters are rejecting the split-roll scheme in counties like Fresno (40-60%), Tulare (64-36%) Riverside (40-60%) and Sacramento (53-47%). Making the comeback more difficult is the fact the measure is on course for defeat in the major coastal counties of San Diego (44-56%) and Orange (39-61%).

Mary-Beth Moylan, associate dean at University of the Pacifics McGeorge School of Law who also supervises the publication of the universitys California Initiative Review, said the opponents succeeded in hammering home their claim that increased commercial property taxes would eventually trickle down to consumers.

The no side did a good job of saying This isnt a tax that will only be against corporations, its going to impact small businesses, Moylan said.

Proposition 19

California would crack down on longstanding tax breaks for inherited homes but allow older residents the ability to take their cushy property tax rates with them when they move under a closely contested ballot measure.

In a race too close to call as of Friday morning, Proposition 19 was leading by a 51-49% margin.

Backed by Newsom along with realtor and firefighter groups, Proposition 19 is meant to give seniors wishing to move within the state more flexibility. If passed, homeowners over the age of 55 as well as those with certain disabilities and wildfire victims could keep their property tax bill with them if they sell and move to a more expensive place.

Supporters say the change could spur more seniors to downsize or move into retirement centers and carries the bonus of increasing housing supply.

Prop 19 will open up tens of thousands of homes that havent been on the market for decades, creating opportunities for new buyers and helping to stabilize housing costs so more Californians can afford home ownership, the supporters claim on their website.

The proposal, placed on the ballot by the Democrat-controlled Legislature, also purports to raise new revenue for local governments and fire departments, as it would increase the tax hit on in-family property transfers.

Led by the Howard Jarvis Taxpayers Association, the opponents argue the change would punish those simply looking to pass on family homes to their children or grandchildren. They note a similar proposal was nixed by voters in 2018.

This is a billion-dollar tax increase on California families, the taxpayers association warns. The price is too high.

Much like the related split-roll proposal, the residential tax reform proposal has performed well in the San Francisco Bay Area as well San Diego and Ventura counties. But supporters remain on edge as the measure hasnt run up more than 60% support in any county and there isnt a clear result as Proposition 19 is ahead by only 336,000 votes.

Proposition 14

Two decades after greenlighting a taxpayer-funded stem cell research agency, California voters are on the verge of approving billions more to find a cure for chronic diseases and cancers.

Ahead by a 51-49% margin, Proposition 14 would allow the state to sell up to $5.5 billion in bonds to prop the California Institute for Regenerative Medicine and its efforts to fight everything from Parkinsons disease, diabetes, stroke and infectious diseases including Covid-19.

After a ban on federal funding for stem cell research during the George W. Bush administration, researchers in 2004 turned to the state ballot. They ultimately convinced voters by a 59-41% margin to create a constitutional right to study stem cell cures as well as take on $3 billion in new debt.

Since 2004, nearly a dozen states including New York and Maryland have created similar programs but on a much smaller scale.

Now the backers seek to keep the institute afloat with another $5.5 billion infusion that could ultimately cost $7.8 billion to pay off. Supporters include Newsom, the University of California Board of Regents and the American Association for Cancer Research.

Critics countered that private stem cell research has made great strides since 2004 and that the federal funding ban was lifted under President Barack Obama. With the state mired in recession, the editorial boards of several California newspapers concluded it was bad timing for Proposition 14 and urged readers to vote no.

The latest update from the Secretary of State shows over 50% support for Proposition 14 in coastal counties like San Diego, Los Angeles and San Francisco. It has effectively been shut out of the Central Valley and rural counties.

The tight race shows that California voters are cognizant of the states shattered finances and are not overly enthusiastic about inking new bonds during a recession, said Moylan, the UOP professor. She says though the initiative is close, the critics seem to have made a persuasive pitch.

People are not in the mood for bonds; they are concerned about the finances of the state and are not feeling like expenditures or committing money down the line is a great idea, she said.

Like Loading...

Follow this link:
Many Initiatives Still Too Close to Call in California - Courthouse News Service

Stem Cell Therapy Market is estimated to be worth USD 8.5 Billion by 2030 – PRnews Leader

The success of approved stem cell therapies has caused a surge in interest of biopharma developers in this field; many innovator companies are currently progressing proprietary leads across different phases of clinical development, with cautious optimism

Roots Analysis has announced the addition of Global Stem Cells Market: Focus on Clinical Therapies, 20202030 (Based on Source (Allogeneic, Autologous); Origin (Adult, Embryonic); Type (Hematopoietic, Mesenchymal, Progenitor); Lineage (Amniotic Fluid, Adipose Tissue, Bone Marrow, Cardiosphere, Chondrocytes, Corneal Tissue, Cord Blood, Dental Pulp, Neural Tissue Placenta, Peripheral Blood, Stromal Cells); and Potency (Multipotent, Pluripotent)) report to its list of offerings.

There is a growing body of evidence supporting the vast applicability and superiority of treatment outcomes of stem cell therapies, compared to conventional treatment options. In fact, the unmet needs within this domain have spurred the establishment of many start-ups in recent years.

To order this 500+ page report, which features 185+ figures and 220+ tables, please visit this link

Key Market Insights

Over 280 stem cell therapies are under development, most of which are allogeneic products More than 50% of the pipeline candidates are in the mid to late phase trials (phase II and above), and allogenic therapies (majority of which are derived from the bone marrow) make up 65% of the pipeline.

70% of pipeline candidates are based on mesenchymal stem cells It is worth highlighting that the abovementioned therapies are designed to treat musculoskeletal (22%), neurological (21%) and cardiovascular (15%) disorders. On the other hand, hematopoietic stem cell-based products are mostly being evaluated for the treatment of oncological disorders, primarily hematological malignancies.

Close to 85% stem cell therapy developers are based in North America and Asia-Pacific regions Within these regions, the US, China, South Korea and Japan, have emerged as key R&D hubs for stem cell therapies. It is worth noting that majority of the initiatives in this domain are driven by small / mid-sized companies

Over 1,500 grants were awarded for stem cell research, since 2015 More than 45% of the total amount was awarded under the R01 mechanism (which supports research projects). The NCI, NHLBI, NICHD, NIDDK, NIGMS and OD emerged as key organizations that have offered financial support for time periods exceeding 25 years as well.

Outsourcing has become indispensable to R&D and manufacturing activity in this domain Presently, more than 80 industry / non-industry players, based in different regions across the globe, claim to provide contract development and manufacturing services to cater to the unmet needs of therapy developers. Examples include (in alphabetical order) Bio Elpida, Cell and Gene Therapy Catapult, Cell Tech Pharmed, GenCure, KBI Biopharma, Lonza, MEDINET, Nikon CeLL innovation, Roslin Cell Therapies, WuXi Advanced Therapies and YposKesi.

North America and Asia-Pacific markets are anticipated to capture over 80% share by 2030 The stem cell therapies market is anticipated to witness an annualized growth rate of over 30% during the next decade. Interestingly, the market in China / broader Asia-Pacific region is anticipated to grow at a relatively faster rate.

To request a sample copy / brochure of this report, please visit this link

Key Questions Answered

The USD 8.5 billion (by 2030) financial opportunity within the stem cell therapies market has been analyzed across the following segments:

The report features inputs from eminent industry stakeholders, according to whom stem cell therapies are currently considered to be a promising alternatives for the treatment of a myriad of disease indications, with the potential to overcome challenges associated with conventional treatment options. The report includes detailed transcripts of discussions held with the following experts:

The research covers brief profiles of several companies (including those listed below); each profile features an overview of the company, financial information (if available), stem cell therapy portfolio and an informed future outlook.

For additional details, please visit https://www.rootsanalysis.com/reports/view_document/stem-cells-market/296.html

or email [emailprotected]

You may also be interested in the following titles:

Contact:

Gaurav Chaudhary +1 (415) 800 3415 +44 (122) 391 1091 [emailprotected]

Visit link:
Stem Cell Therapy Market is estimated to be worth USD 8.5 Billion by 2030 - PRnews Leader

Cancer Stem Cell Therapeutics Market Outlooks 2020: Size, Cost Structures, Growth rate and Industry Analysis to 2027 – Eurowire

Cancer Stem Cell Therapeutics Market Report

The research study on the Global Cancer Stem Cell Therapeutics Market is a thorough investigation of the value and supply chain of the market and offers all-inclusive data about the industry. The report also covers insightful information about pricing, cost, value, capacity, gross revenue, and profit margins with reference to historical analysis and forecast estimation. The report also strives to identify demands and trends in different sectors of the Cancer Stem Cell Therapeutics market in major geographies of the world.

The Cancer Stem Cell Therapeutics market has witnessed dynamic changes in trends and demands owing to the ongoing COVID-19 pandemic. The report provides a detailed outlook on how the pandemic has affected the key segments of the Cancer Stem Cell Therapeutics industry. The report includes an in-depth impact analysis of the COVID-19 pandemic on the overall Cancer Stem Cell Therapeutics industry and covers a futuristic impact scenario.

Get a sample of the report @ https://www.reportsanddata.com/sample-enquiry-form/1414

The report studies the market dynamics to identify and scrutinize the strategic initiatives and tactics undertaken by the industry players in order to gain a robust footing in the market and to achieve a substantial global position. It provides exhaustive analysis and imparts insightful data to help the readers understand the Cancer Stem Cell Therapeutics industry in detail and gain a competitive advantage over other players. The report also provides strategic recommendations to new and emerging players to help them formulate better entry and investment strategies.

The report covers extensive analysis of the key market players in the market, along with their business overview, expansion plans, and strategies. The key players studied in the report include:

Merck KGA, LONZA Group AG, Novartis, Osiris Therapeutics, Pfizer, Pfizer, Stemline Therapeutics Inc., STEMCELL Technologies, and Thermo Fischer Scientific Inc.

The report offers a comprehensive analysis of the Cancer Stem Cell Therapeutics market inclusive of product portfolio, categories, applications, and a comprehensive analysis of the value chain structure. The study investigates several factors influencing the growth of the market and provides a competitive advantage to the readers.

The Cancer Stem Cell Therapeutics market report is an investigative study that provides insights into opportunities, limitations, and barriers encountered by the companies that influence or hinder the growth of the industry. Overall the report provides valuable information and an overview of the market scenario to gain a better understanding of the market.

Request a discount on the report @ https://www.reportsanddata.com/discount-enquiry-form/1414

Treatment Type: (Revenue, USD Million; 20162026)

Disease Type: (Revenue, USD Million; 20162026)

Application: (Revenue, USD Million; 20162026)

End Use: (Revenue, USD Million; 20162026)

The report covers an extensive regional analysis and market estimation in each region and covers key geographical regions such as North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa.

To read more about the report, visit @ https://www.reportsanddata.com/report-detail/cancer-stem-cell-therapeutics-market

Key Point Summary of the Report:

Thank you for reading our report. For further queries, please connect with us to know more about the report and its customization. Our team will ensure the report is customized accurately to meet your requirements.

Take a look at other reports from Reports and Data on PR Newswire:

Spine Biologics Market: Spine Biologics Market to Reach USD 2,629.6 Million By 2027 | CAGR: 3.9%

Isobutanol Market: Isobutanol Market to Reach USD 1555.8 Million By 2027 | CAGR: 6.4%

Hematology Analyzers and Reagents Market: Hematology Analyzers and Reagents Market to Reach USD 12.10 Billion By 2027

Isobutanol Market: Isobutanol Market to Reach USD 1555.8 Million By 2027 | CAGR: 6.4%

About Us:

Our in-house experts assist our clients with advice based on their proficiency in the market that helps them in creating a compendious database for the clients. Our team offers expert insights to clients to guide them through their business ventures. We put in rigorous efforts to keep our clientele satisfied and focus on fulfilling their demands to make sure that the end-product is what they desire. We excel in diverse fields of the market and with our services extending to competitive analysis, research and development analysis, and demand estimation among others, we can help you invest your funds in the most beneficial areas for research and development. You can rely on us to provide every significant detail you might need in your efforts to make your business flourish.

Contact Us:

John Watson

Head of Business Development

Reports and Data|Web:www.reportsanddata.com

Direct Line:+1-212-710-1370

E-mail:[emailprotected]

Connect with us:Blogs|LinkedIn|Twitter

Go here to read the rest:
Cancer Stem Cell Therapeutics Market Outlooks 2020: Size, Cost Structures, Growth rate and Industry Analysis to 2027 - Eurowire

Biologics Safety Testing Market Research Report by Test Type, by Application – Global Forecast to 2025 – Cumulative Impact of COVID-19 – Yahoo Finance…

Globe Newswire

Dublin, Nov. 05, 2020 (GLOBE NEWSWIRE) -- The "Technology Landscape, Trends and Opportunities in the Global Flexible Packaging Market" report has been added to ResearchAndMarkets.com's offering. This report analyzes technology maturity, degree of disruption, competitive intensity, market potential, and other parameters of various technologies in the flexible packaging market. The technologies in flexible packaging have undergone significant change in recent years, with semi flexible packaging to advance flexible packaging. The rising wave of new technologies such as bio plastics based flexible packaging are creating significant potential in food and beverage, cosmetic and toiletries, and healthcare applications, due to their better protection and recycling benefits.In this market, various technologies, such as plastic film based flexible packaging, aluminium based flexible packaging, paper based flexible packaging, and bio plastic based flexible packaging technologies are used in various applications. Growing demand for bio-based PLA films in various applications and increased shelf life of the products are creating new opportunities for various flexible packaging technologies.The study includes technology readiness, competitive intensity, regulatory compliance, disruption potential, trends, forecasts and strategic implications for the global flexible packaging technology by application, technology, and region.Some of the flexible packaging companies profiled in this report include Bemis Company, Mondi, Huhtamaki Group, Amcor Limited, and BASF.This report answers the following 9 key questions: Q.1 What are some of the most promising and high-growth technology opportunities for the flexible packaging market?Q.2 Which technology will grow at a faster pace and why?Q.3 What are the key factors affecting dynamics of different technologies? What are the drivers and challenges of these technologies in flexible packaging market?Q.4 What are the levels of technology readiness, competitive intensity and regulatory compliance in this technology space?Q.5 What are the business risks and threats to these technologies in flexible packaging market?Q.6 What are the latest developments in flexible packaging technologies? Which companies are leading these developments?Q.7 Which technologies have potential of disruption in this market?Q.8 Who are the major players in this flexible packaging market? What strategic initiatives are being implemented by key players for business growth?Q.9 What are strategic growth opportunities in this flexible packaging technology space? Key Topics Covered: 1. Executive Summary2. Technology Landscape2.1. Technology Background and Evolution2.2. Technology and Application Mapping2.3. Supply Chain3. Technology Readiness3.1. Technology Commercialization and Readiness3.2. Drivers and Challenges in Flexible Packaging Technologies3.3. Competitive Intensity3.4. Regulatory Compliance4. Technology Trends and Forecasts analysis from 2013-20244.1. Flexible Packaging Opportunity4.2. Technology Trends (2013-2018) and Forecasts (2019-2024)4.2.1. Plastic Film based Flexible Packaging4.2.2. Aluminium based Flexible Packaging4.2.3. Paper based Flexible Packaging4.2.4. Bio Plastic based Flexible Packaging4.3. Technology Trends (2013-2018) and Forecasts (2019-2024) by Application Segments4.3.1. Food and Beverage4.3.1.1. Plastic Film based Flexible Packaging4.3.1.2. Aluminium based Flexible Packaging4.3.1.3. Paper based Flexible Packaging4.3.1.4. Bio Plastic based Flexible Packaging4.3.2. Healthcare4.3.3. Cosmetics and Toiletries4.3.4. Other5. Technology Opportunities (2013-2024) by Region5.1. Flexible Packaging Market by Region5.2. North American Flexible Packaging Market5.3. European Flexible Packaging Market5.4. APAC Flexible Packaging Market5.5. ROW Flexible Packaging Market6. Latest Development and Innovation in Flexible Packaging Technologies7. Companies/Ecosystem7.1. Product Portfolio Analysis7.2. Market Share Analysis7.3. Geographical Reach8. Strategic Implications8.1. Implications8.2. Growth Opportunity Analysis8.2.1. Growth Opportunities for the Flexible Packaging Market by Material Technology8.2.2. Growth Opportunities for the Flexible Packaging Market by Application8.2.3. Growth Opportunities for the Flexible Packaging Market by Region8.3. Emerging Trends in the Flexible Packaging Market8.4. Disruption Potential8.5. Strategic Analysis8.5.1. New Product Development8.5.2. Capacity Expansion of the Flexible Packaging Market8.5.3. Mergers, Acquisitions, and Joint Ventures in the Flexible Packaging Market9. Company Profiles of Leading Players9.1. Bemis Company9.2. Mondi9.3. Huhtamaki Group9.4. Amcor Limited9.5. BASF For more information about this report visit https://www.researchandmarkets.com/r/xp7gvs Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research. CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood, Senior Press Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900

Read the rest here:
Biologics Safety Testing Market Research Report by Test Type, by Application - Global Forecast to 2025 - Cumulative Impact of COVID-19 - Yahoo Finance...